Israel
Minovia Therapeutics is a clinical-stage international biotechnology research company focused on treatment innovation for mitochondrial disease. The company is developing Mitochondrial Augmentation Technology (MAT), a cell therapy platform using allogeneic isolated mitochondria to augment various cell types for therapeutic products. Their lead product, MNV-201, is currently in clinical trials for Pearson Syndrome and in the pre-clinical stage for Myelodysplastic Syndrome (MDS), showing promising clinical and pre-clinical proof-of-concept for primary mitochondrial diseases and age-related bone marrow failures. Minovia has developed novel mitochondria-based biomarkers for patient stratification known as "MitoScore." The company is at the forefront of cell therapy quality, focusing on mitochondrial science and developing robust analytical methods to measure cellular mitochondrial function and modalities to rescue mitochondrial dysfunction in different cell therapies.
Founded in 2012, Minovia Therapeutics is pioneering innovative approaches to address mitochondrial dysfunction, a critical area within biotechnology. With a focus on mitochondrial disease, the company's research and development efforts hold significant promise for addressing unmet medical needs in this space. The clinical trials and pre-clinical stage advancements of MNV-201 demonstrate a commitment to developing impactful treatments for a range of mitochondrial-related conditions. Minovia's advancements in biomarker development and cell therapy quality measurement further underscore their dedication to driving progress within the biotechnology sector.
